| |  Online-Ressource |
|---|
| Verfasst von: | Christopoulos, Petros [VerfasserIn]  |
|---|
| | Kirchner, Martina [VerfasserIn] |
|---|
| | Bozorgmehr, Farastuk [VerfasserIn] |
|---|
| | Magios, Nikolaus [VerfasserIn] |
|---|
| | Kazdal, Daniel [VerfasserIn] |
|---|
| | Volckmar, Anna-Lena [VerfasserIn] |
|---|
| | Brückner, Lena Marie [VerfasserIn] |
|---|
| | Bochtler, Tilmann [VerfasserIn] |
|---|
| | Kriegsmann, Mark [VerfasserIn] |
|---|
| | Endris, Volker [VerfasserIn] |
|---|
| | Penzel, Roland [VerfasserIn] |
|---|
| | Kriegsmann, Katharina [VerfasserIn] |
|---|
| | Eichhorn, Martin E. [VerfasserIn] |
|---|
| | Herth, Felix [VerfasserIn] |
|---|
| | Heußel, Claus Peter [VerfasserIn] |
|---|
| | El-Shafie, Rami [VerfasserIn] |
|---|
| | Schneider, Marc [VerfasserIn] |
|---|
| | Muley, Thomas [VerfasserIn] |
|---|
| | Meister, Michael [VerfasserIn] |
|---|
| | Schirmacher, Peter [VerfasserIn] |
|---|
| | Bischoff, Helge [VerfasserIn] |
|---|
| | Griesinger, Frank [VerfasserIn] |
|---|
| | Stenzinger, Albrecht [VerfasserIn] |
|---|
| | Thomas, Michael [VerfasserIn] |
|---|
| Titel: | Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing |
|---|
| Verf.angabe: | P. Christopoulos, M. Kirchner, J. Roeper, F. Saalfeld, M. Janning, F. Bozorgmehr, N. Magios, D. Kazdal, A.L. Volckmar, L.M. Brückner, T. Bochtler, M. Kriegsmann, V. Endris, R. Penzel, K. Kriegsmann, M. Eichhorn, F.J.F. Herth, C.P. Heussel, R.A. El Shafie, M.A. Schneider, T. Muley, M. Meister, M. Faehling, J.R. Fischer, L. Heukamp, P. Schirmacher, H. Bischoff, M. Wermke, S. Loges, F. Griesinger, A. Stenzinger, M. Thomas |
|---|
| E-Jahr: | 2020 |
|---|
| Jahr: | 22 August 2020 |
|---|
| Umfang: | 8 S. |
|---|
| Fussnoten: | Gesehen am 19.01.2021 ; Im Titel ist das Pluszeichen hochgestellt |
|---|
| Titel Quelle: | Enthalten in: Lung cancer |
|---|
| Ort Quelle: | Amsterdam [u.a.] : Elsevier, 1985 |
|---|
| Jahr Quelle: | 2020 |
|---|
| Band/Heft Quelle: | 148(2020), Seite 105-112 |
|---|
| ISSN Quelle: | 1872-8332 |
|---|
| Abstract: | Objective - Panel-based next-generation sequencing (NGS) is increasingly used for the diagnosis of EGFR-mutated non-small-cell lung cancer (NSCLC) and could improve risk assessment in combination with clinical parameters. - Materials and methods - To this end, we retrospectively analyzed the outcome of 400 tyrosine kinase inhibitor (TKI)-treated EGFR+ NSCLC patients with validation of results in an independent cohort (n = 130). - Results - EGFR alterations other than exon 19 deletions (non-del19), TP53 co-mutations, and brain metastases at baseline showed independent associations of similar strengths with progression-free (PFS hazard ratios [HR] 2.1-2.3) and overall survival (OS HR 1.7-2.2), in combination defining patient subgroups with distinct outcome (EGFR+ NSCLC risk Score, "ENS", p < 0.001). Co-mutations beyond TP53 were rarely detected by our multigene panel (<5%) and not associated with clinical endpoints. Smoking did not affect outcome independently, but was associated with non-del19 EGFR mutations (p < 0.05) and comorbidities (p < 0.001). Laboratory parameters, like the blood lymphocyte-to-neutrophil ratio and serum LDH, correlated with the metastatic pattern (p < 0.01), but had no independent prognostic value. Reduced ECOG performance status (PS) was associated with comorbidities (p < 0.05) and shorter OS (p < 0.05), but preserved TKI efficacy. Non-adenocarcinoma histology was also associated with shorter OS (p < 0.05), but rare (2-3 %). The ECOG PS and non-adenocarcinoma histology could not be validated in our independent cohort, and did not increase the range of prognostication alongside the ENS. - Conclusions - EGFR variant, TP53 status and brain metastases predict TKI efficacy and survival in EGFR+ NSCLC irrespective of other currently available parameters ("ENS"). Together, they constitute a practical and reproducible approach for risk stratification of newly diagnosed metastatic EGFR+ NSCLC. |
|---|
| DOI: | doi:10.1016/j.lungcan.2020.08.007 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1016/j.lungcan.2020.08.007 |
|---|
| | Volltext: https://www.lungcancerjournal.info/article/S0169-5002(20)30579-1/pdf |
|---|
| | Resolving-System: https://doi.org/10.1016/j.lungcan.2020.08.007 |
|---|
| | DOI: https://doi.org/10.1016/j.lungcan.2020.08.007 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Brain metastases |
|---|
| | EGFR NSCLC |
|---|
| | mutation |
|---|
| | Overall survival |
|---|
| | Treatment failure |
|---|
| | Tyrosine kinase inhibitor |
|---|
| K10plus-PPN: | 1744946647 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing / Christopoulos, Petros [VerfasserIn]; 22 August 2020 (Online-Ressource)
